Article
A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
Gut - 1 Apr 2013
Tian Sun, Simon Iris, Moreno Victor, Roepman Paul, Tabernero Josep, Snel Mireille, van't Veer Laura, Salazar Ramon, Bernards Rene, Capella Gabriel
Abstract excerpt
OBJECTIVE: To develop gene expression profiles that characterise KRAS-, BRAF- or PIK3CA-activated- tumours, and to explore whether these profiles might be helpful in predicting the response to the epidermal growth factor receptor (EGFR) pathway inhibitors better than mutation status alone. DESIGN: Fresh frozen tumour samples from 381 colorectal cancer (CRC) patients were collected and mutations in KRAS, BRAF and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.